Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

pricing

This page shows the latest pricing news and features for those working in and with pharma, biotech and healthcare.

Segmentation, evolved

Segmentation, evolved

However, what this is telling us is less about pricing and precision medicine and more about an evolutionary adaption to market conditions known as contextual segmentation. ... Sanofi has done so via contextual segmentation, then targeting a specific

Latest news

More from news
Approximately 89 fully matching, plus 800 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    What could this look like? Potential solutions could include innovative payment models, such as evolving funding pathways, innovative pricing that shifts from the product to the solution, and splitting the burden ... treatments. There is also the

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    Budget silos. “Globally and in the UK, we are leading in this area because we are collaborating, being transparent about our intent, across different countries looking at pricing arrangements. ... Patients have a lot more power than they realise.”.

  • Drug pricing

    Healthcare terms - Drug pricing.

  • Healthcare Glossary

    Search and browse hundreds of industry specific terms and phrases or suggest your own terms and definitions. Balanced Scorecard. A management tool used by organisations to monitor and manage performance against defined objectives. It began as a

  • Market access

    Healthcare terms - Market access.

More from intelligence
Approximately 16 fully matching, plus 132 partially matching documents found.

Latest appointments

  • Claes Buxfeldt joins NDA Claes Buxfeldt joins NDA

    He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.

  • Mereo BioPharma appoints head of patient access and commercial planning Mereo BioPharma appoints head of patient access and commercial planning

    In this role, Hughes-Wilson was responsible for Sobi’s commercialisation approach and led pricing, reimbursement and access teams for the group’s rare disease product portfolio.

  • W2O bolsters its commercialisation offering W2O bolsters its commercialisation offering

    W2O bolsters its commercialisation offering. Rita Glaze joins the firm as leader of value, pricing and market access practice. ... Glaze has 25 years’experience in the biopharmaceutical and life science sector with expertise in marketing, managed

  • Hanover Brussels appoints Aurélie Marchand as account director Hanover Brussels appoints Aurélie Marchand as account director

    Coming from a country where market access and negotiations around pricing and reimbursement can be challenging, I’m eager to bring this experience to the EU level.”.

  • RJW & Partners appoints new director RJW & Partners appoints new director

    RJW &Partners appoints new director. Cathy Beecher joins from ICON. Pricing and market access group RJW &Partners, a subsidiary of Mission Group, has appointed Cathy Beecher as its new director. ... She joins the firm from pharma service provider ICON,

More from appointments
Approximately 2 fully matching, plus 26 partially matching documents found.

Latest from PMHub

  • Value Genome LLC

    Value Genome LLC. Assisting mid to late stage clinical development prepare for their first commercialization specializing in market access strategies, medical affairs, health economics, pricing and reimbursement.

  • A roadmap to strategic drug pricing

    A roadmap to strategic drug pricing. The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. ... Pharma firms must identify products that will benefit from innovative pricing models, and then forge the types

  • Can rare diseases be a viable option for the pharma industry?

    A deviation of only 1 or 2 patients will have an acute impact on any clinical trial plans, commercial forecasts, health outcomes study or pricing strategy. ... Pricing and reimbursement. By addressing only a small group of patients, the price of

  • Remap Consulting

    Remap Consulting. Remap Consulting is a specialist pharmaceutical pricing and market access consultancy. ... Our mission is to help solve your pricing and market access challenges to ensure improved patient access to your products.

  • CMR to feature in new healthcare documentary

    This valuable information informs product development, pricing models and marketing communications which in turn creates better outcomes for patients and HCPs.” George Ashford, CMR.

More from PMHub
Approximately 6 fully matching, plus 55 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia